RE: Hypertension and increased serum clozapine associated with clozapine and fluoxetine in combination
Sir -In their case report Sloan and O'Boyle 1 suggest that the elevation of serum clozapine and norclozapine with the combination of clozapine and fluoxetine is through the inhibition of the cytochrome P450 CYP2D6 isozyme, and that due consideration should be given to the genetic variation of this enzyme in clinical practice. Although an in vitro study 2 has demonstrated that clozapine is metabolised by CYP2D6, subsequent findings have demonstrated that there is a lack of association between clozapine metabolism and debrisoquine and S-mephenytoin hydroxylation polymorphism, 3 and that the CYP2D6 genotype does not affect clozapine clearance. 4 These studies suggest that CYP2D6 may not be involved in metabolism of clozapine in vivo. We would like to propose that the more likely mechanism underlying the increased serum clozapine levels is mediated by the altered activity of CYP3A4. This enzyme which is involved in the metab-olism of clozapine, is also inhibited by fluoxetine and thus would lead to elevation of clozapine concentrations' when these two drugs are prescribed concomitantly.
Siow-Ann Chong, MBBS, MMed(Psych)
Fellow, Gary Remington, MD, PhD, FRCP(C) Director, Medication Assessment Programme, Schizophrenia Division, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
RE: Clozapine-fluoxetine and the CYP450 system
Sir -We thank Chong and Remington for their letter and interesting comments, and would like to add that there is still controversy in the literature over which of the various subtypes of cytochrome P450 are responsible for the metabolism of clozapine. 1 CYP1A2, CYP2D6 and CYP3A4 have all been found to be involved in the metabolism clozapine, and much of the evidence points toward CYP1A2 as being the most important. 1 ' CYP3A4 is not the major isoenzyme involved in the metabolism of clozapine, and while fluoxotene and its metabolite norfluoxetine have been shown to inhibit CYP3A4 this effect is minimal. 4 It is certainly possible that inhibition of this isoenzyme may have contributed to the raised clozapine and norclozapine levels, in our patient, and we accept the cited evidence indicating that CYP2D6 genotype does not effect clozapine clearance. s It is possible however that inhibition of the CYP2D6 system also contributed to the raised clozapine and norclozapine levels by the inhibition of a metabolic step distal to clozapine N-dealkylation ie. inhibition of secondary resulting in raised plasma levels of clozapine and norclozapine, but no change in the plasma clozapine/norclozapine ratio. 1 Furthermore the antidepressant medication nefazodone, which is a known CYP3A4 inhibitor has been shown to have no effect on clozapine metabolism.' Thus further clarification of the role of the different cytochromes involved in the metabolism of clozapine is warranted, and we would still advocate caution when coadministering drugs which have proven inhibitory action on the cytochrome P450 isoenzyme.
